Drug Repurposing: progress, challenges and recommendations

Published by Nature Reviews Drug Discovery

Drug DiscoveryDrug RepurposingResearch and Drug Development

In this Article, it is presented approaches used for Drug Repurposing (also known as drug repositioning), discussed the challenges faced by the repurposing community and recommended innovative ways by which these challenges could be addressed to help realize the full potential of Drug Repurposing.

View this resource Bookmark this resource

Repurposing Medicines Toolkit – Guidance for navigating the process

Published by Life Arc, Medical Research Council (MRC)

GuidelineLife ArcRepurposing

this toolkit aims to provide a guide for researchers, charities and others embarking on repurposing projects. It highlights common activities, issues and considerations at each development stage and signpost to other available resources. The content is mostly styled as questions – what should I be considering at each development stage? It is intended to stimulate thinking and not as a step-by-step guide, which reflects the variable nature of repurposing.

View this resource Bookmark this resource

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force

Published by Orphanet J Rare Dis.

Data MiningDrug RepurposingIRDIRC

(IRDiRC) set up the multi-stakeholder Data Mining and Repurposing (DMR) Task Force to examine the potential of applying biomedical data mining strategies to identify new opportunities to use existing pharmaceutical compounds in new ways and to accelerate the pace of drug development for rare disease patients.

View this resource Bookmark this resource

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force

Published by Orphanet J Rare Dis.

Data MiningDrug Repurposing

This article reviews the past successes of data mining for Drug Repurposing, and planning for future biomedical research capacity, the DMR Task Force identified four strategic infrastructure investment areas to focus on in order to accelerate rare disease research productivity and drug development: (1) improving the capture and sharing of self-reported patient data, (2) better integration of existing research data, (3) increasing experimental testing capacity, and (4) sharing of rare disease research and development expertise. Additionally, the DMR Task Force also recommended a number of strategies to increase data mining and repurposing opportunities for rare diseases research as well as the development of individualized and precision medicine strategies.

View this resource Bookmark this resource

Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses)

Published by NCATS

Repurposing

The New Therapeutic Uses program aims to improve the process of developing new treatments and cures for disease by finding new uses for assets that already have cleared several key steps along the development path (also known as Drug Repurposing).

View this resource Bookmark this resource

Discovering New Therapeutics Uses for Existing Molecules (NTU) program, National Center for Advancing Translational Sciences (NCATS)

Published by IRDiRC

Drug RepurposingFundingNCATSNTU-NCATSOrphan DrugResearch and Drug Discovery

The NTU program aims to improve the process of developing new treatments for diseases by finding new uses for existing therapies that already have cleared several key steps along the development path. Existing or partially developed therapeutic candidates can be repurposed for use in new disease indications

View this resource Bookmark this resource

This manual is a comprehensive resource for early drug discovery, providing guidelines for developing therapeutic hypotheses, validating targets and pathways, and establishing proof of concept criteria. It includes analyses of costs at various stages of drug development. The content encompasses critical decision-making points in New Chemical Entity (NCE) development, exploratory Investigational New Drug (IND) processes, and orphan drug designation. Furthermore, it delves into Drug Repurposing and drug delivery technologies, making it an invaluable guide for professionals initiating new drug discovery and development programs.

View this resource Bookmark this resource